Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues
Phase of Trial: Phase IV
Latest Information Update: 28 Aug 2019
Price : $35 *
At a glance
- Drugs Tenofovir disoproxil fumarate (Primary) ; Nucleotide reverse transcriptase inhibitors
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms STOP
- 28 Aug 2019 Primary endpoint has been met. (Sustained response, defined as the presence of an HBV DNA level 2000 IU/ml at week 48 in patients with a combined response at baseline)
- 28 Aug 2019 Status changed from recruiting to completed, according to results published in the Gut.
- 28 Aug 2019 Results (n=67) published in the Gut.